Can-Fite Biopharma Good News
We learned, from Petach Tikva, Israel, that Can-Fite Biopharma (CANF) – a biotechnology company advancing its pipeline of small molecule drugs that address inflammatory, cancer and liver diseases, announced its completion of enrollment of all patients (>400) planned for its Phase 3 Comfort™ study with the firm’s product Piclidenoson in patients with moderate to severe plaque psoriasis.
Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug. According to the press release, the favorable therapeutic index of the product was demonstrated in Phase 2 clinical studies. It is currently being evaluated in a multinational Phase 3 study as a treatment for moderate to severe psoriasis and a Phase 2 U.S. study for moderate to severe COVID-19.
Positive Data from the Comfort Study
Positive interim data analysis from this Phase 3 study was released by Can-Fite Biopharma in October 2020. The Independent Data Monitoring Committee (IDMC) recommended, based on positive data, that the firm continues the study. At this point, the Company has completed the enrolment of all patients for this study and plans to release topline results in Q1 2022.